title: Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
abstract: Alzheimer's disease (AD) is characterized by a variety of cognitive deficits which can be reliably assessed by the neuropsychological test battery of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), but the cerebral changes underlying the respective cognitive deficits are only partly understood. Measures of severity of dementia in AD as well as delayed episodic memory performance in mild cognitive impairment significantly correlated with bihemispheric cerebral glucose hypometabolism. We therefore hypothesized that the CERAD cognitive battery may represent cerebral dysfunction of both hemispheres in patients with AD. In 32 patients with AD, cerebral glucose metabolism was investigated using positron-emission-tomography with 18Fluorodeoxyglucose (FDG PET) and associated with the test scores of the CERAD cognitive battery by statistical parametric mapping. Episodic memory scores significantly correlated with temporopari etal glucose metabolism of both hemispheres while delayed episodic memory significantly was correlated with the right frontotemporal cortices. Verbal fluency and naming scores significantly correlated with glucose metabolism in left temporoparietal and right frontal cortices, whereas constructional praxis predominantly correlated significantly with the bilateral precuneus. In conclusion, the results of our study demonstrate that not only memory function but also functions of language and constructional praxis in AD are associated with glucose metabolism as revealed by FDG PET in subsets of uni- and bilateral brain areas. The findings of our study for the first time demonstrate that in AD neuropsychological deficits as assessed by the CERAD refer to different cerebral sites of both hemispheres.
authors.affiliation: Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany. Peter.Schoenknecht@medizin.uni-leipzig.de
authors.forename: Oskar Dieter Peter
authors.initials: OD
authors.lastname: Schönknecht
authors.forename: Aoife
authors.initials: A
authors.lastname: Hunt
authors.forename: Pablo
authors.initials: P
authors.lastname: Toro
authors.forename: Thomas
authors.initials: T
authors.lastname: Guenther
authors.forename: Marcus
authors.initials: M
authors.lastname: Henze
authors.forename: Uwe
authors.initials: U
authors.lastname: Haberkorn
authors.forename: Johannes
authors.initials: J
authors.lastname: Schröder
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000503:physiopathology*; D001931:Brain Mapping / Q000379:methods; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D003072:Cognition Disorders / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000503:physiopathology*; D004292:Dominance, Cerebral / Q000502:physiology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D011939:Mental Recall; D008875:Middle Aged; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography / Q000379:methods*; D012042:Registries; D012720:Severity of Illness Index
chemical_list: D019788:Fluorodeoxyglucose F18; D005947:Glucose